Core Viewpoint - In 2025, Danaher is enhancing its investment and localization strategies in China amidst a complex international landscape and increasing geopolitical tensions [3]. Group 1: Investment and Localization Strategies - Danaher has deepened its presence in China by increasing local investments, with multiple products transitioning to local production and several new products launched from domestic R&D and manufacturing bases in the first half of 2025 [3]. - The Shanghai R&D and manufacturing base of Meigu Molecular supports over 70% of Danaher's global capacity, featuring seven production lines that are continuously expanding [7]. - Leica Microsystems is transitioning several high-end microscope product lines to its Shanghai facility, with plans to invest 200 million yuan to upgrade its R&D and manufacturing base [12]. Group 2: New Product Launches - The QPi x Flex microbial screening system, developed and manufactured in Shanghai, aims to streamline microbial workflows and enhance experimental efficiency across various fields [6]. - The Cyt oFLEX mosaic spectral flow cytometer, developed by Beckman Coulter Life Sciences, offers versatile detection capabilities for laboratory needs [11]. - Pall Corporation has introduced locally manufactured filtration products, including the Pall Gas Kleen® 1.5 nm filter and Pall UCA CMP products, enhancing precision and throughput in semiconductor applications [13]. Group 3: R&D and Production Facilities - Cy tiva has established a new cell culture medium development base in Shanghai, investing nearly 20 million yuan to provide comprehensive, customized development services for local pharmaceutical companies [14]. - The Cy tiva ReadyKleer XDR single-use bioreactor bags have commenced production in Beijing, addressing the growing demand in the biopharmaceutical sector [15]. - Leica's Suzhou facility has officially begun commercial production of immunohistochemistry reagent products, marking a significant step in local R&D and manufacturing capabilities [18].